Valeritas Annual Revenue, Number of Employees, Growth and Funding


Bridgewater, NJ USA
Total Funding:$333.9M
Industry:Medical Equip
Lead Investor(s):CRG L.P

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Valeritas's estimated annual revenue is currently $26.4M per year.
  • Valeritas received $23.7M in venture funding in May 2016.
  • Valeritas's estimated revenue per employee is $145,044
  • Valeritas's total funding is $333.9M.

Employee Data

  • Valeritas has 182 Employees.
  • Valeritas grew their employee count by 21% last year.
  • Valeritas currently has 4 job openings.

Executive Contacts

Scott HuieVP, RA/QA and Compliance
Matthew NguyenSVP Commercial
Chris GregoryVP of R&D
Christopher DunnArea Business Director - Central and West US
Carla NikkelSenior Director Medical Affairs
Scott AbbottDirector, New Product Commercialization
Jim SlevinSenior Director, Account Management
Bardsson LarrabeeDirector of Marketing
Doug WinklerNational Account Director
Mona GormanDirector of Training & Leadership Development

We are a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. We designed our first commercialized product, the V-Go Wearable Insulin Delivery Device, or V-Go, to help patients with Type 2 diabetes who require insulin to achieve and maintain their target blood glucose goals. V-Go is indicated for continuous subcutaneous infusion of insulin over 24 hours at preset rates and on-demand bolus dosing in two-unit increments in adult patients requiring insulin. V-Go is a small, discreet and easy-to-use disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by using one type of insulin (fast-acting) at a continuous preset (background) basal rate over a 24-hour period and provides on-demand bolus dosing for meals and snacks. In numerous real-world analyses V-Go has consistently shown to lower A1C's with less insulin. The discreet and convenient basal-bolus insulin delivery method provided by V-Go empowers patients to simplify their insulin management thereby mitigating the need to plan their daily routine around multiple daily injections. V-Go is cleared for use in the United States and the E.U. is commercially available in the United States.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals


Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
ACTEON North Am...
Topcon Medical ...
Hausmann Indust...
Oticon USA
NextPhase Medic...
A&E Medical
Flowonix Medica...

Valeritas News

08/15/2019 - Clinical Trial Evaluating Delivery of Regular Human Insulin vs ...

Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas' V-Go® Meets Primary A1c Endpoint.

08/29/2019 - Valeritas Reports Inducement Grants Under NASDAQ Listing ...

BRIDGEWATER, N.J., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and ...

09/03/2019 - Valeritas Announces Oral Presentation of Preclinical h-Patch ...

BRIDGEWATER, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and ...

Valeritas Funding

DateAmountRoundLead InvestorsReference
2011-09-13$150.0MCWelsh Carson Anderson and StowArticle
2013-06-05$100.0MUndisclosedCapital Royalty L PArticle
2016-05-05$23.7MUndisclosedCRG L.PArticle

Valeritas Executive Hires

2006-09-14John E. TimberlakeEVPArticle
2006-11-10Poul StrangeChf Scientific OfficerArticle
2006-12-26Tara CharvatVP Mktg/Mktg OperationsArticle
2007-06-20Mike StoutVP Sales/SalesOperationsArticle
2009-06-02Kristine PetersonCEOArticle
2010-03-18James E. DentzerCFOArticle
2016-02-26John TimberlakeInterim CEOArticle
2016-08-17Erick J. LuceraCFOArticle
2017-06-08Peter DevlinChairmanArticle
2018-01-10Joseph SaldanhaChief Business OfficerArticle